Updated:
ALS Association
The ALS Association funds more ALS research than any nonprofit outside the US government, with over $200M deployed since 1985.
ALS Association
The ALS Association was founded in 1985 as a patient advocacy and research funding organization dedicated to amyotrophic lateral sclerosis, a progressive neurodegenerative disease. Its national office sits in Washington, DC, and it coordinates with a network of local chapters that deliver care services and raise funds in communities across the country. The organization funds scientific research through grants, fellowships, and its own TREAT ALS research portfolio, which spans drug discovery, clinical trials, and biomarker development. It also operates a network of Certified Treatment Centers of Excellence — academic medical centers that provide multidisciplinary care to people with ALS. Beyond research, the association advocates for federal policies that accelerate therapy approvals, expand access to Social Security Disability Insurance, and increase NIH and Department of Defense research budgets. A significant portion of its public visibility came from the 2014 Ice Bucket Challenge, which generated $115 million in donations and directly enabled the discovery of the NEK1 gene linked to ALS. The organization reported over $40 million in annual revenue in recent filings, with the majority coming from public contributions and fundraising events. It maintains accreditation from the Better Business Bureau's Wise Giving Alliance and holds a four-star rating from Charity Navigator. The leadership team includes Calaneet Balas as President and CEO and a board of trustees drawn from medicine, business, and the ALS community. The association's connected philanthropic structure is a public charity, not a private foundation or family office — grants are awarded through a peer-reviewed process, and the organization is governed by independent trustees. Structurally, the ALS Association operates less like an investment vehicle and more like a disease-focused grantmaker that blends research funding with direct patient services. Its capital allocation is entirely mission-driven — there is no return-seeking portfolio, and its beneficiaries are scientists and patients rather than limited partners. This distinguishes it from venture-philanthropy models or endowed medical foundations that manage large investment pools.
General information
Firm type
Foundation
Year founded
1985
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Washington
Corporate office
Washington, DC, United States
Principals
Calaneet Balas
President and CEO
Sector focus
Frequently asked questions
Who runs the ALS Association's operations and grantmaking decisions?
Calaneet Balas serves as President and CEO, leading a team that includes a Chief Scientific Officer and a Chief of Care Services. Research grants are awarded through a peer-reviewed process advised by external scientific experts, not by a single investment committee or family principal. The organization is governed by an independent board of trustees.
How does the ALS Association fund its research and care programs?
The association is a public charity funded primarily by individual donations, corporate partnerships, and fundraising events such as Walk to Defeat ALS. The 2014 Ice Bucket Challenge alone raised $115 million. Unlike an endowment-funded foundation, it must continually raise new funds each year to sustain its grant cycles and care services.
Does the ALS Association maintain an endowment or investment portfolio that institutions can co-invest alongside?
No. The ALS Association is a grantmaking public charity, not an investment firm or endowed foundation. It does not operate a return-seeking portfolio, nor does it take equity positions in biotech companies. Institutional allocators looking for exposure to ALS therapeutic development should evaluate the venture-backed biotech companies that receive its research grants, not the association itself.
What is the ALS Association's known posture on co-investments or partnerships with venture capital firms?
The association does not co-invest alongside external GPs or make for-profit investments. Its relationship with industry is through research partnerships and clinical trial support, not through equity ownership. It has partnered with pharmaceutical companies and biotech firms to accelerate therapy development, but these are grant-based or collaborative research arrangements.
How is the ALS Association related to the ALS Therapy Development Institute or other ALS-focused research entities?
The ALS Association is a separate nonprofit from the ALS Therapy Development Institute, which operates a research lab in Cambridge, Massachusetts. The association has funded ALS TDI through grants and maintains a complementary mission — but they are independent organizations with different operating models. The association is a grantmaker; ALS TDI is a research institute that also raises public donations.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: